Richard Friedman to Hemorrhage
This is a "connection" page, showing publications Richard Friedman has written about Hemorrhage.
Connection Strength
0.317
-
Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty. Arterioscler Thromb Vasc Biol. 2015 Apr; 35(4):771-8.
Score: 0.105
-
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res. 2010 Sep; 126(3):175-82.
Score: 0.075
-
Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin Appl Thromb Hemost. 2009 Sep-Oct; 15 Suppl 1:25S-31S.
Score: 0.071
-
Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. Vasc Health Risk Manag. 2014; 10:157-67.
Score: 0.025
-
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thromb Res. 2012 Aug; 130(2):147-51.
Score: 0.021
-
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011 Apr; 105(4):721-9.
Score: 0.020